Injectable anabolic androgenic steroid
Methenolone Enanthate (Primobolan Depot)
Methenolone Enanthate (Primobolan Depot) after one dose: 50% at ~10.5 days, 25% at 21 days, 12.5% at 31.5 days.
Drawn from the half-life in the app's model, ~10.5 days. The model's figures
- Compound
- Methenolone Enanthate (Primobolan Depot)
- Symbol
- PRI
- Family
- Other steroids
- Parts
- 14
- References
- 29
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Methenolone enanthate is the injectable enanthate ester of methenolone, an anabolic androgenic steroid, and Notter, in Acta Radiologica in 1975, names the product "Metenolone Enanthate (Primobolan Depot)".3,4 A 2021 review by Tauchen and colleagues in Molecules says metenolone "has been used in the form of acetate and enanthate esters, the former being orally active, while the latter is given by injection".4 The review adds that metenolone has "weak androgenic and oestrogenic activity and low hepatotoxicity" and "has been discontinued for medicinal use in many countries".4
The human studies cited below were published between 1968 and 2011 and used methenolone enanthate, or methenolone where the ester is not named, in breast cancer, aplastic and other refractory anemias, liver cirrhosis, osteoporosis and stroke rehabilitation.5,6 None of the sources cited here is a drug label, and a search of the US DailyMed database by drug name, for methenolone and for primobolan, returned 0 labels.
How it works
Sources in this part
Kicman, in the British Journal of Pharmacology in 2008, writes that injectable anabolic steroids usually have the 17β-hydroxyl group esterified "to prevent rapid absorption from the oily vehicle" and that "Once in the circulation, hydrolysis rapidly occurs by the action of blood esterases to yield the active compound".7 The list of injectable esters in his text names esters of nandrolone, testosterone, boldenone and trenbolone and does not name an ester of methenolone; his Figure 3 caption names esters by number only.7
Kicman summarises Saartok and colleagues, 1984, who compared androgen receptor binding in cytosol from rat skeletal muscle, rat prostate and rabbit skeletal muscle, and reports the order of relative binding affinity, against methyltrienolone, as nandrolone, then methenolone, then testosterone, then mesterolone, "relatively high and generally similar affinity", in animal tissue and for methenolone itself rather than its enanthate.7 He adds that "There is a large discrepancy as to what is known about the in vivo activities of these steroids compared with their in vitro activity".7
Bond and colleagues, in Frontiers in Endocrinology in 2022, write that other commonly used AAS are "already 5α-reduced, such as methenolone" and others.8 None of the cited sources reports a measurement of whether methenolone enanthate is converted to estrogen in people; Tauchen and colleagues describe metenolone as having "weak androgenic and oestrogenic activity".4
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~10.5 days
- Bioavailability
- 95%
- Typical dose
- 150–750 mg/week
- Route
- IM
- Time to peak
- ~72 h
Sources in this part
The app gives methenolone enanthate a half-life of ~10.5 days (252 hours), a bioavailability of 95%, a time to peak of ~72 h, an intramuscular route and a typical dose of 150–750 mg/week. A search of PubMed on 16 November 2026 for methenolone with half-life, pharmacokinetics or plasma concentration returned 15 records, and none of the sources cited here reports a half-life, bioavailability or time to peak for methenolone enanthate.
| Measure | App figure | Source figure |
|---|---|---|
| Half-life | ~10.5 days (252 h) | None of the cited sources reports a half-life for methenolone enanthate, and Kicman gives no figure for a methenolone ester.7 |
| Bioavailability | 95% | None of the cited sources reports a bioavailability for methenolone enanthate. |
| Time to peak | ~72 h | None of the cited sources reports a time to peak for methenolone enanthate. |
| Duration of activity | ~14 days (336 h) | None of the cited sources reports a duration of activity for methenolone enanthate. |
| Route | IM | Tauchen and colleagues state that the enanthate "is given by injection", and Okamoto and colleagues injected it "intramuscularly weekly".4,6 |
| Typical dose | 150–750 mg/week | The studies cited report 100 to 1,200 mg per week, as set out in the dose table below.6,3 |
The chart below draws the app's one-compartment model for methenolone enanthate, using the app's half-life of 252 hours and time to peak of about 72 hours. It is an illustration, not a measured level, and no cited source reports a measured level of methenolone enanthate. The one interval it lists as studied is once weekly, as in the stroke trial of Okamoto and colleagues, 2011.6 The dose slider runs from 25 to 750 mg, the upper end of the app's typical dose.
Level over 6 weeks
Level, as a share of the peak after one 100 mg dose
As studied: every 7 days6.
An illustration from a pharmacokinetic model using a half-life of 252 hours (10.5 days). It is not a measured level or a suggested dose.
Human studies
Lockner, 1979, and Hartmann and colleagues, 1981, name the drug as methenolone or metenolone and not the ester.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Notter, 19753 | Patients treated with Metenolone Enanthate (Primobolan Depot); no comparison group described. | 43 patients with disseminated or inoperable carcinoma of the breast; 41 evaluable. | 400 to 1,200 mg/week for at least 3 months. | Objective remissions lasting longer than 3 months in 8 of 41 evaluable patients; soft tissue metastases responded best; liver and brain metastases unaffected. |
| Hartmann and colleagues, 19819 | Records of women treated with metenolone; the record's chemical index lists the enanthate and the acetate. | 66 women with metastasized breast carcinoma. | Not stated. | Remission in 26, mean duration 8.2 (3-29) months; treatment interrupted in 4 because of cholestasis, pulmonary embolism and hypercalcaemia. |
| Garbrecht and colleagues, 198110 | Lipid metabolism during additive methenolone oenanthate (Primobolan). | 28 menopausal women with metastasizing carcinoma of the breast. | Not stated. | Hyperlipoproteinaemia type IIa in ten and type IIb in two; one of the latter had a myocardial infarction during treatment; regressed in every case once methenolone was stopped. |
| Lockner, 197911 | Therapeutic trial of methenolone (Primobolan); ester not named. | 19 consecutive patients with refractory anemia. | Not stated. | Remissions: pancytopenia 3/6, bicytopenia 2/4, refractory anemia with hyperplastic marrow 1/5, myelofibrosis 1/4; no obvious prolongation of survival in responders. |
| Krug, 198012 | Own clinical series with metenolonenanthat (Primobolan-S). | 26 patients with aplastic anaemia: 15 idiopathic and 11 toxically conditioned. | At least two months needed to judge, per the author. | About as many therapeutic failures as good results or partial remissions; thrombocytopenia persisted in most partial remissions. |
| Knöbel and Becker, 197513 | Albumin turnover measured before and after treatment; control group of patients for baseline comparison. | 15 patients with compensated liver cirrhosis. | 200 mg per week for four weeks. | Albumin turnover, reduced in cirrhosis, was enlarged by the steroid, more so the lower it had been. |
| Almustafa and colleagues, 199214 | Before-and-after serial spine radiographs, no randomised control described, on calcium alone or with oestradiol valerate, testosterone oenanthate or methenolone oenanthate. | 49 patients with osteoporosis: 30 postmenopausal, 19 nonmenopausal. | Mean 3.2 and 4.4 years on calcium with sex hormones; doses not stated. | Fracture rate scores per thousand patient-years fell to 20 and 207 from 1500 and 1697 (postmenopausal and nonmenopausal groups; p less than 0.001 each) on calcium with sex hormones, while calcium alone showed no significant change (p = 0.144 and p = 0.017); methenolone not separated from the other hormones; the record's text is truncated. |
| Shimodozono and colleagues, 201015 | Prospective observer-blinded open-label nonrandomized controlled trial; controls had rehabilitation alone. | 25 inpatients with hemiplegia 1 to 8 months after stroke: 14 steroid, 11 control. | 100 mg intramuscularly once a week for 6 weeks, with strength training. | Nonparetic lower limb only; peak torque rose significantly from each group's own baseline in 9 of 10 conditions at 2 weeks and 8 of 10 at 6 weeks, against 1 and 5 in controls; the authors write that the combination "tended to have a positive effect"; no contraindications encountered. |
| Okamoto and colleagues, 20116 | Randomized to a metenolone enanthate group or controls. | 26 hemiplegic stroke patients in subacute rehabilitation. | 100 mg intramuscularly weekly for 6 weeks. | Thigh muscle area rose 13.4% (affected side) and 14.5% (unaffected), against 3.3% and 5.2% in controls. |
Deeper analysis: Notter, Acta Radiologica, 1975
Notter reports 43 patients with disseminated or inoperable breast carcinoma who received Metenolone Enanthate (Primobolan Depot) at 400 to 1,200 mg per week for at least 3 months, and 8 of 41 evaluable patients had objective remissions lasting longer than 3 months.3 The author writes that "The therapeutic efficiency of Primobolan Depot is comparable to that of testosterone propionate but the agent is less virilising".3 The record describes no comparison arm, so the comparison with testosterone propionate is the author's statement.3 The record carries no funding statement, author-tie statement or stated limitations.3
Deeper analysis: the two stroke trials, Shimodozono 2010 and Okamoto 2011
Okamoto and colleagues, whose first author is at Fujita Health University in Japan, randomly assigned 26 hemiplegic stroke patients in subacute rehabilitation to metenolone enanthate, 100 mg intramuscularly weekly for 6 weeks, or to a control group.6 Thigh muscle cross-sectional area, measured by computed tomography, rose 13.4% (affected side) and 14.5% (unaffected side) against 3.3% and 5.2% in controls.6 In the steroid group the correlation between the initial Functional Independence Measure motor subscore and the area increase at 6 weeks was -0.754 for the affected side and -0.567 for the unaffected side, against 0.199 and 0.431 in the control group, and the authors write that the increase "was most prominent in patients with a low initial FIM-M score".6 The authors tested the steroid "without the addition of specific training" and measured thigh cross-sectional area, and conclude that "ME administration is effective for improving muscle CSA and, thus, muscle strengthening in stroke rehabilitation", an inference from area rather than a strength measure.6 The record carries the publication type "Research Support, Non-U.S. Gov't" and names no funder, author ties, limitations or adverse events.6
Shimodozono and colleagues, with an address at the School of Medical and Dental Sciences in Kagoshima, Japan, gave the same weekly dose for 6 weeks to 14 inpatients with hemiplegia and compared them with 11 who had rehabilitation alone, in an observer-blinded, open-label nonrandomized trial.15 They conclude that "the combination of AAS and muscle strength training tended to have a positive effect on muscle strength after stroke", and the record names no funder and no limitations beyond that design.15
Registry entry for an enrolling study
ClinicalTrials.gov record NCT07568574, sponsored by Enhanced Emirates Limited, describes a study that started on 12 March 2026 with an estimated 60 adults and lists "Methenolone Enanthate (Primobolan)" as an intervention, with an "Intramuscular injection administered for up to 25 weeks".16 The record, last verified in April 2026, gives the status as enrolling by invitation, describes "individualized PES regimens", and states no outcome for methenolone enanthate alone.16
Doses reported in studies
The app's typical dose is 150–750 mg/week. The doses the cited studies report are below; the lowest, 100 mg a week, is under the app's range, and the highest, 1,200 mg a week in Notter's series, is above it.6,3
| Source | People | Dose reported | Schedule and length |
|---|---|---|---|
| Okamoto and colleagues, 20116 | Hemiplegic stroke patients, subacute rehabilitation | 100 mg | Intramuscular injection weekly for 6 weeks |
| Shimodozono and colleagues, 201015 | Hemiplegia 1 to 8 months after stroke | 100 mg metenolone enanthate | Intramuscular injection once a week for 6 weeks |
| Knöbel and Becker, 197513 | Compensated liver cirrhosis | 200 mg per week | Four weeks |
| Notter, 19753 | Disseminated breast carcinoma | 400 to 1,200 mg/week | At least 3 months |
Side effects reported
Sources in this part
- 3Notter, 1975
- 9Hartmann et al., 1981
- 10Garbrecht et al., 1981
- 11Lockner, 1979
- 15Shimodozono et al., 2010
- 17Menon, 2003
- 18Shiozawa et al., 1982
- 19Androgen therapy of aplastic anaemia: a prospective study of 352 cases, 1979
- 20Edvardsson, 2015
- 21Socas et al., 2005
- 22Ramos-Villalobos et al., 2009
- 23Geissler et al., 1995
- 24Ozdemir et al., 2013
- 25Gurses et al., 2024
- Hartmann and colleagues, whose record for 66 women treated with metenolone lists both the enanthate and the acetate, report "In most cases the treatment was well tolerated", and that in four the treatment was interrupted because of cholestasis, pulmonary embolism and hypercalcaemia.9
- Garbrecht and colleagues report hyperlipoproteinaemia type IIa in 10 of 28 women and type IIb in two, one of whom had a myocardial infarction during treatment, with "no relationship between the level of hypercholesterolaemia and the methenolone dosage" and regression once treatment stopped.10
- Lockner writes that in 19 patients with refractory anemias, treated with methenolone and the ester not named, "Side-effects were negligible", and the record's indexing terms also list drug-induced liver injury, virilism as chemically induced and agranulocytosis, without rates.11 Shimodozono and colleagues write that in 14 treated stroke patients "no contraindications for AAS were encountered".15
- Notter's record lists hirsutism and hoarseness among its indexing terms as chemically induced, and the author calls the agent "less virilising" than testosterone propionate, in a record that describes no comparison arm.3
- Menon, in Fertility and Sterility in 2003, reports a bodybuilder with persistent azoospermia and male hypogonadotropic hypogonadism who had used seven anabolic steroids, including methenolone enanthate, so the finding cannot be attributed to it alone; semen analyses returned to normal after 3 months of treatment with hCG and hMG.17
- Several records name methenolone among other drugs, so none attributes an event to methenolone enanthate alone. Shiozawa and colleagues, in Annals of Neurology in 1982, report that 3 of 27 patients with hypoplastic anemia given male hormone and protein-assimilating hormone developed superior sagittal sinus thrombosis, and the record lists methenolone enanthate among the substances.18 A 1979 prospective study of 352 patients with aplastic anaemia on androgens, which lists methenolone among its drugs, states "Signs of liver damage were observed no matter which was the drug used" and an actuarial mortality of 52% at the 20th month.19 Edvardsson, 2015, and Socas and colleagues, 2005, report hypertensive encephalopathy and hepatocellular adenomas in bodybuilders, and each record lists methenolone enanthate among several steroids.20,21
- Two further records name methenolone with the ester unstated or the acetate: a 2009 letter titled "Pulmonary toxicity due to methenolone", whose record has a title only, and Geissler and colleagues, 1995, whose title reports a "severe adverse effect caused by metenolone acetate" in a man with aplastic anemia, with cholestasis in its index terms.22,23
Animal studies
Ozdemir and colleagues gave 0.5 mg/kg of metenolone enanthate intraperitoneally to pubertal Sprague-Dawley rats, 5 times a week for 4 weeks, and reported higher left ventricular mass and left ventricular hypertrophy in female rats, while left ventricular mass in male rats was similar to controls, a condition the authors call "more evident" in females.24 Gurses and colleagues, evaluating methenolone enanthate against osteonecrosis of the jaw in 36 rats, two groups of which were given zoledronic acid, reported a lower bone exposure rate in the group also given methenolone enanthate (10%) than in the group given zoledronic acid alone (75%), and six rats died during the experimental research without the groups being given; the record lists funding from the Selcuk University Research Foundation.25
None of the PubMed records of the cited studies reports a liver enzyme result for methenolone enanthate.
Bloodwork and markers
Sources in this part
The app lists total testosterone, free testosterone, estradiol, hematocrit, lipids and PSA as markers for methenolone enanthate. Among the PubMed records of the cited studies, only Garbrecht and colleagues report a lipid result, the hyperlipoproteinaemia types IIa and IIb above, and Knöbel and Becker report a change in albumin turnover.10,13 None of the PubMed records of the cited studies reports total or free testosterone, estradiol, hematocrit or PSA for methenolone enanthate.
What tested products contained
Sources in this part
Three studies of anabolic steroid products include samples labelled methenolone enanthate: two sets of samples that people who use steroids in Australia submitted, and one set of formulations seized by French law enforcement.26,27,28
Deeper analysis: Piatkowski and colleagues, Harm Reduction Journal, 2025
Piatkowski and colleagues (Griffith University in Queensland, Australia, and other affiliations) tested anabolic steroid samples that community members submitted to two drug-checking sites between 19 April and 16 August 2024.26 The paper's testing table lists three samples with the expected compound Methenolone Enanthate (Primobolan): one at 200 mg/mL with no brand given in wave 1, and in wave 2 one at 100 mg/mL from Chief Labs and one at 200 mg/mL from Polar.26 In all three the detected compound was methenolone enanthate, and the table gives "N/A" for whether the concentration was as expected and no detected concentration, including for the two Wave 2 samples, with no explanation of the N/A entries.26 The study was funded by the Queensland Mental Health Commission.26 Several authors declare that they are volunteer members of The Loop Australia, "a national organisation for drug checking and drug checking research", and one author is its chief executive.26 On limitations, the authors write that "our testing approach evolved considerably from Wave 1 to Wave 2" and that in Wave 1 "purity analysis was limited, with only one sample undergoing such assessment", whereas in Wave 2 they "expanded our testing protocol to include a comprehensive purity analysis".26
Deeper analysis: Craven and colleagues, Drug and Alcohol Review, 2025
Craven and colleagues analysed 28 anonymously donated samples (16 injectable, 10 oral, 2 raw powders) at an independent forensic laboratory and reported that 15 were mislabelled or mis-sold.27 In the text, methenolone enanthate (n = 2) "ranged from 75 to 190 mg/mL (132 ± 81 mg/mL)", and the paper's table gives the labelled dosage as "Not provided" and records testosterone cypionate as "found instead in one sample".27 The testing was facilitated and funded by PEDTest Australia, a private business led by an author of the paper, who is its chief executive.27 The authors state that "The small sample size, while significant, may not be representative of the broader Australian AAS market".27
Deeper analysis: Balayssac and colleagues, Molecules, 2025
Balayssac and colleagues, at laboratories of the Université de Toulouse, analysed AAS formulations seized by French law enforcement, using nuclear magnetic resonance.28 In the first set of 20 formulations, injectable sample 17 was labelled methenolone enanthate and methenolone enanthate was the compound detected.28 In a second set of 12 oil-based injectables, sample OI-6 was labelled methenolone at 120 mg/mL and the testosterone esters detected were cypionate at 69 ± 4 mg/mL and propionate at 41 ± 2 mg/mL, and the heatmap analysis reports "no other AAS appears to be present in these formulations", so no methenolone was reported in OI-6.28 The authors write that "all the twelve analyzed injectable formulations were of poor quality, with a mismatch between the advertised and actual contents".28 The study reports no external funding and no conflicts of interest.28
Regulatory and anti-doping status
The World Anti-Doping Agency's 2026 Prohibited List, in force from 1 January 2026, places anabolic agents in S1 as "prohibited at all times", and S1.1 lists metenolone among the anabolic androgenic steroids "when administered exogenously".1 The list names metenolone and does not name an ester of it, and it states that all prohibited substances in the class are non-Specified Substances.1 In the United States, 21 CFR 1308.13(f) places substances meeting the anabolic steroid definition in Schedule III, "including its salts, esters and ethers", and lists methenolone as item (49), unless specifically excepted or listed in another schedule.2
Detection in testing
Fragkaki and colleagues, whose affiliations include the Doping Control Laboratory of Athens, gave methenolone to two healthy male volunteers, collected urine for up to 12 and 26 days, and report eight sulfate metabolites, four of them the most abundant and long-term detectable; the record does not state the ester or the dose.29
What is not known
Sources in this part
- The half-life, time to peak, bioavailability and duration of activity of methenolone enanthate are not reported in the sources cited here.7
- The PubMed records of the older studies carry no funding statement, no statement of author ties and no stated limitations.
- The sources cited do not say in which countries a methenolone enanthate product is currently authorised; the US DailyMed database, searched by drug name only, returned 0 labels.
Frequently asked questions
Sources in this part
- 1World Anti-Doping Agency, 2026
- 2US Drug Enforcement Administration
- 3Notter, 1975
- 4Tauchen et al., 2021
- 6Okamoto et al., 2011
- 7Kicman, 2008
- 9Hartmann et al., 1981
- 10Garbrecht et al., 1981
- 11Lockner, 1979
- 12Krug, 1980
- 13Knobel et al., 1975
- 14Almustafa et al., 1992
- 26Piatkowski et al., 2025
- 27Craven et al., 2025
- 28Balayssac et al., 2025
What is the half-life of methenolone enanthate?
The app gives methenolone enanthate a half-life of ~10.5 days (252 hours), and none of the cited sources reports a half-life for the enanthate. Kicman writes that the duration of action of injectable esters depends on the rate of absorption from the site of administration, and gives no figure for a methenolone ester.7
Is methenolone enanthate banned by WADA?
Metenolone is named on the WADA 2026 Prohibited List in S1.1 among the anabolic androgenic steroids "when administered exogenously", and anabolic agents are prohibited at all times, in and out of competition.1
Is methenolone enanthate a controlled substance in the US?
Methenolone is item (49) in the Schedule III anabolic steroid list of 21 CFR 1308.13(f), which covers "its salts, esters and ethers" unless specifically excepted or listed in another schedule.2
What is Primobolan Depot?
What is the difference between methenolone enanthate and methenolone acetate?
Tauchen and colleagues write that metenolone has been used as acetate and enanthate esters, "the former being orally active, while the latter is given by injection".4
What was methenolone enanthate studied for in people?
What side effects are reported for methenolone enanthate?
Two of these three reports name the drug without a stated ester. In 66 women, Hartmann and colleagues, whose record lists both enanthate and acetate, report that treatment with metenolone was interrupted in four because of cholestasis, pulmonary embolism and hypercalcaemia.9 Garbrecht and colleagues, who name the oenanthate, report hyperlipoproteinaemia in 12 of 28 women, one with a myocardial infarction, which regressed once treatment stopped.10 Lockner, with the ester not named, writes that "Side-effects were negligible" in 19 patients.11
Does methenolone enanthate aromatise?
None of the cited sources reports a measurement of aromatisation of methenolone in people. Tauchen and colleagues describe metenolone as having "weak androgenic and oestrogenic activity".4
Is methenolone enanthate toxic to the liver?
Tauchen and colleagues state that metenolone has "low hepatotoxicity", and none of the PubMed records of the cited studies reports a liver enzyme result for the enanthate.4 Hartmann and colleagues, whose record lists both enanthate and acetate, report that treatment was interrupted in four of 66 women because of cholestasis, pulmonary embolism and hypercalcaemia, without saying how many had cholestasis.9
What did tests of products labelled methenolone enanthate find?
In Piatkowski and colleagues' 2025 drug-checking table, all three samples labelled methenolone enanthate (Primobolan) contained methenolone enanthate, with no concentration result given.26 In Craven and colleagues' 2025 table, methenolone enanthate was measured at 75 to 190 mg/mL against a labelled dosage of "Not provided", and testosterone cypionate was "found instead in one sample".27 In Balayssac and colleagues' 2025 analysis of seized injectables, one labelled methenolone enanthate contained it, while one labelled methenolone at 120 mg/mL contained testosterone cypionate and propionate and no methenolone.28
Guides, tools and comparisons
References
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. In force 1 January 2026. WADA Prohibited List 2026
- US Drug Enforcement Administration. 21 CFR 1308.13, Schedule III. Electronic Code of Federal Regulations. 21 CFR 1308.13
- Notter G. Treatment of disseminated carcinoma of the breast by metenolone enanthate. Acta Radiol Ther Phys Biol 1975. PMID 1224996
- Tauchen J, et al. Medicinal Use of Testosterone and Related Steroids Revisited. Molecules 2021. PMC7919692
- Kennedy BJ, Yarbro JW. Effect of methenolone enanthate (NSC-64967) in advanced cancer of the breast. Cancer 1968. PMID 4952912
- Okamoto S, Sonoda S, Tanino G, et al. Change in thigh muscle cross-sectional area through administration of an anabolic steroid during routine stroke rehabilitation in hemiplegic patients. Am J Phys Med Rehabil 2011. PMID 21173687
- Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol 2008. PMC2439524
- Bond P, Smit DL, de Ronde W. Anabolic-androgenic steroids: How do they work and what are the risks? Front Endocrinol 2022. PMC9837614
- Hartmann F, et al. Anabole Therapie bei metastasierendem Mamma-Karzinom. Med Klin 1981. PMID 7311930
- Garbrecht M, et al. Hyperlipoproteinamie bei additiver Behandlung des metastasierenden Mammakarzinoms mit Metenolonenanthat. Dtsch Med Wochenschr 1981. PMID 7215163
- Lockner D. Treatment of refractory anemias with methenolone. Acta Med Scand 1979. PMID 367090
- Krug K. Beitrag zur Pathophysiologie der aplastischen Anamie und deren Behandlung mit Metenolonenanthat. Z Gesamte Inn Med 1980. PMID 7467606
- Knobel H, Becker K. Die Wirkung eines anabol wirkenden Steroids (Metenolonenanthat) auf den intra- und extravasalen Albuminpool bei Leberzirrhose. Z Gastroenterol 1975. PMID 1224752
- Almustafa M, et al. Effects of treatments by calcium and sex hormones on vertebral fracturing in osteoporosis. Q J Med 1992. PMID 1321457
- Shimodozono M, et al. Addition of an anabolic steroid to strength training promotes muscle strength in the nonparetic lower limb of poststroke hemiplegia patients. Int J Neurosci 2010. PMID 20707637
- Enhanced Emirates Limited. Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes: A Hybrid Design in a Real-World Setting. ClinicalTrials.gov NCT07568574. Posted 2026. NCT07568574
- Menon DK. Successful treatment of anabolic steroid-induced azoospermia with human chorionic gonadotropin and human menopausal gonadotropin. Fertil Steril 2003. PMID 12801577
- Shiozawa Z, Yamada H, Mabuchi C, et al. Superior sagittal sinus thrombosis associated with androgen therapy for hypoplastic anemia. Ann Neurol 1982. PMID 7159062
- Androgen therapy of aplastic anaemia: a prospective study of 352 cases. Scand J Haematol 1979. PMID 472658
- Edvardsson B. Hypertensive encephalopathy associated with anabolic-androgenic steroids used for bodybuilding. Acta Neurol Belg 2015. PMID 25319132
- Socas L, Zumbado M, Perez-Luzardo O, et al. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med 2005. PMID 15849280
- Ramos-Villalobos G, Antonio-Gullon Blanco J, Gonzalez-Martin I. Pulmonary toxicity due to methenolone: a case report. Arch Bronconeumol 2009. PMID 19875221
- Geissler RG, Ganser A, Kaltwasser JP, Hoelzer D. Partial remission and severe adverse effect caused by metenolone acetate in a male patient with aplastic anemia. Eur J Haematol 1995. PMID 7615051
- Ozdemir O, Bozkurt I, Ozdemir M, Yavuz O. Side effect of metenolone enanthate on rats heart in puberty: morphometrical study. Exp Toxicol Pathol 2013. PMID 23280519
- Gurses G, Sur E, Cengiz ZO, Korez MK. Evaluation of Methenolone Enanthate Efficacy in Preventing MRONJ: A Randomized Trial on Rats. J Oral Pathol Med 2024. PMID 39113433
- Piatkowski T, Coomber R, Francis C, et al. Anabolic-androgenic steroid testing as a tool for consumer engagement and harm reduction: a sequential explanatory mixed-method study. Harm Reduct J 2025. PMC12231991
- Craven A, Ferris J, Nielsen S, et al. Lead Astray? The Hidden Contaminants in Australian Anabolic-Androgenic Steroid Market and Their Potential Health Impact. Drug Alcohol Rev 2025. PMC12405805
- Balayssac S, Assemat G, Danoun S, et al. Quantitative 1H and 13C NMR and Chemometric Assessment of 13C NMR Data: Application to Anabolic Steroid Formulations. Molecules 2025. PMC12074264
- Fragkaki AG, et al. Comparison of sulfo-conjugated and gluco-conjugated urinary metabolites for detection of methenolone misuse in doping control by LC-HRMS, GC-MS and GC-HRMS. J Mass Spectrom 2015. PMID 26259657